Lebrikizumab

2024年10月30日，礼来（NYSE：LLY）发布2024年第三季度（报告期）财报，期内公司收入114.39亿元，同比增长20%，主要由药品销量增长15%和药价上涨驱动。销量增长的主要推动因素为替尔泊肽的销售增长。 美国市场收入78.1亿美元，总比增长46%，主要由替尔泊肽（Zepbound和Mounjaro）推动 按市场划分 美国市场收入78.1亿美元，总比增长46%，主要由替尔泊肽（Zepbound和Mounjaro）推动，但度拉糖肽（Trulicity）的下滑（-22%）抵消了一部分增长。 美国以外地区收入下降12%至36.3亿美元，原因是销量下降10%，以及2023 年第三季度出售奥氮平产品组合权利所致。 排除奥氮平产品组合，美国以外地区收入和销量分别增长33%和36%，主要得益于替尔泊肽（Mounjaro）和阿贝西利（Verzenio）的贡献。 替尔泊肽自2023年11月上市以来迅速放量，成为礼来的主要销售驱动因素 第三季度Mounjaro（用于2型糖尿病）营收31亿美元，Zepbound（用于体重管理）营收13亿美元； 前三季度，Mounjaro营收80亿美元，Zepbound营收30亿美元。 其他产品中（报告期内） 自免产品依奇珠单抗（Taltz）销售额8.8亿美元，同比增长18%； 恩格列净（Jardiance）销售额6.86亿美元，同比下滑2%； 赖脯胰岛素（Humalog）销售额5.35亿美元，同比增长35%。 产品管线方面 Ebglyss在美国获批用于治疗患有中度至重度特应性皮炎； Kisunla在日本获批用于治疗阿尔茨海默病。 公司前三季度收入315.1亿美元，同比增长27%。目前公司正在加大投资增加替尔泊肽供应，并2024年全年收入预期上调至 454~460亿美元之间。 全球医疗情报领导者 解锁隐藏在数据中的商业潜力  关于 G B I ” 自从2002年成立以来，GBI始终以技术为驱动，为药企、器械及行业相关服务商提供贯穿生命周期的全球药品市场竞争数据、全球行业资讯、HCPs洞察、全国医疗器械数据等商业信息与洞察，助力企业在进行战略布局和决策时，脱颖而出。历经20余年的深耕细作GBI已成为95%以上跨国药企、国内头部药企、咨询与投资机构等医疗圈灯塔用户值得信赖的长期合作伙伴。 联系我们 投稿 | 发稿 | 媒体合作 ▶ zhangxinyue13@baidu.com 数据库 | 咨询服务 | 资讯追踪 ▶ 点击左下“阅读原文”完成表单填写 点击阅读原文，解锁完整双语新闻

Another inflammation and immunology startup has attracted big bucks. On Thursday, Evommune announced a $115 million raise to back a pipeline anticipated to have multiple Phase 2 readouts in the next 18 months. The Series C gives fresh momentum to the Palo Alto startup’s pipeline after it stopped development of its Phase 2a drug, an IRAK4 inhibitor, in atopic dermatitis last September. The biotech quickly rebounded and has a mid-stage test ongoing — with more planned soon — for its MRGPRX2 inhibitor codenamed EVO756. The once-daily oral drug is being explored for chronic inducible urticaria, chronic spontaneous urticaria, atopic dermatitis and other indications. Evommune has a partnership with Maruho for development and commercialization of the asset in certain Asian regions. (Septerna, which went public last week , is also working on MRGPRX2.) The startup also has an IL-18-targeted fusion protein dubbed EVO301 for atopic dermatitis. It will enter Phase 2 in the first three months of next year, CEO Luis Peña told Endpoints News . The California startup licensed the asset from South Korean company AprilBio this summer for $15 million upfront and about $475 million in potential payments, an Evommune spokesperson confirmed to Endpoints at the time of the June announcement . Meanwhile, Evommune could still return to the shelved IRAK4 inhibitor, known as EVO101. An investigator-initiated trial is now testing the drug for hidradenitis suppurativa, a chronic skin condition that has attracted interest in recent years. If those data look good, Evommune might restart development. RA Capital and Sectoral Asset Management co-led the Series C, which comes 18 months after a $50 million Series B . While the new raise gives Evommune multiple years of runway, it could entertain the idea of going public, and its investor syndicate “could easily support an IPO,” Peña said. Around the middle of next year — after releasing its first batch of Phase 2 data for EVO756 in chronic inducible urticaria — could be a good time to explore the public market, Peña said. The biotech might also attract the interest of pharma acquirers, Peña said. Evommune is led by former Dermira executives, who helped take the autoimmune drug developer to a $1.1 billion sale to Eli Lilly in early 2020. “We’re more amenable to that kind of partnership as opposed to actually doing a co-development deal with a company,” Peña said. “We have such deep development expertise that we don’t really need help on that front, but if someone wants to come and bid on our programs or our company at some point, they can.” He declined to comment on whether Evommune has already received takeover proposals. He added that “you should never set up your company that way.” Peña, who was chief development officer of Dermira when Lilly bought it, formed his new startup a week after he left the Indianapolis drugmaker in 2020. The main drug from that buyout, lebrikizumab , was approved by the FDA for eczema last month. Evommune licensed the IRAK4 inhibitor and EVO756, among other programs, from Lilly.